Browse > Article
http://dx.doi.org/10.4014/jmb.2009.09009

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2  

Ku, Keun Bon (Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology)
Shin, Hye Jin (Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology)
Kim, Hae Soo (Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology)
Kim, Bum-Tae (Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology)
Kim, Seong-Jun (Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology)
Kim, Chonsaeng (Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology)
Publication Information
Journal of Microbiology and Biotechnology / v.30, no.12, 2020 , pp. 1843-1853 More about this Journal
Abstract
COVID-19, caused by the novel coronavirus SARS-CoV-2, has spread globally and caused serious social and economic problems. The WHO has declared this outbreak a pandemic. Currently, there are no approved vaccines or antiviral drugs that prevent SARS-CoV-2 infection. Drugs already approved for clinical use would be ideal candidates for rapid development as COVID-19 treatments. In this work, we screened 1,473 FDA-approved drugs to identify inhibitors of SARS-CoV-2 infection using cell-based assays. The antiviral activity of each compound was measured based on the immunofluorescent staining of infected cells using anti-dsRNA antibody. Twenty-nine drugs among those tested showed antiviral activity against SARS-CoV-2. We report this new list of inhibitors to quickly provide basic information for consideration in developing potential therapies.
Keywords
SARS-CoV-2; COVID-19; FDA-approved drugs; repurposing screens;
Citations & Related Records
Times Cited By KSCI : 6  (Citation Analysis)
연도 인용수 순위
1 D'Alessandro S, Scaccabarozzi D, Signorini L, Perego F, Ilboudo DP, Ferrante P, et al. 2020. The use of antimalarial drugs against viral infection. Microorganisms. 8: 85.   DOI
2 Han Y, Mesplede T, Xu H, Quan Y, Wainberg MA. 2018. The antimalarial drug amodiaquine possesses anti-ZIKA virus activities. J. Med. Virol. 90: 796-802.   DOI
3 Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. 2014. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 58: 4885-4893.   DOI
4 Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45: 883-893.   DOI
5 Denning DW. 2003. Echinocandin antifungal drugs. Lancet 362: 1142-1151.   DOI
6 Kim C, Kang H, Kim DE, Song JH, Choi M, Kang M, et al. 2016. Antiviral activity of micafungin against enterovirus 71. Virol. J. 13: 99.   DOI
7 Ho YJ, Liu FC, Yeh CT, Yang CM, Lin CC, Lin TY, et al. 2018. Micafungin is a novel anti-viral agent of chikungunya virus through multiple mechanisms. Antiviral. Res. 159: 134-142.   DOI
8 Mostafa GA, Al-Badr AA. 2011. Buclizine. Profiles Drug Subst. Excip. Relat. Methodol. 36: 1-33.
9 Ansarin K, Tolouian R, Ardalan M, Taghizadieh A, Varshochi M, Teimouri S, et al. 2020. Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial. Bioimpacts 10: 209-215.   DOI
10 Antoszczak M, Maj E, Napiorkowska A, Stefanska J, Augustynowicz-Kopec E, Wietrzyk J, et al. 2014. Synthesis, anticancer and antibacterial activity of salinomycin N-benzyl amides. Molecules 19: 19435-19459.   DOI
11 Lee JY, Kim SJ, Myoung J. 2019. Middle east respiratory syndrome Coronavirus-encoded ORF8b inhibits RIG-I-Like receptors in a differential mechanism. J. Microbiol. Biotechnol. 29: 2014-2021.   DOI
12 Ianevski A, Yao R, Fenstad MH, Biza S, Zusinaite E, Reisberg T, et al. 2020. Potential antiviral options against SARS-CoV-2 infection. Viruses 12: 642.   DOI
13 Vogel JU, Schmidt S, Schmidt D, Rothweiler F, Koch B, Baer P, et al. 2019. The thrombopoietin receptor agonist eltrombopag inhibits human cytomegalovirus replication via iron chelation. Cells 9: 31.   DOI
14 Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270-273.   DOI
15 Cucinotta D, Vanelli M. 2020. WHO Declares COVID-19 a Pandemic. Acta Biomed. 91: 157-160.
16 Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. 2020. The socio-economic Implications of the Coronavirus and COVID-19 Pandemic: a review. Int. J. Surg. 78: 185-193.   DOI
17 Lake MA. 2020. What we know so far: COVID-19 current clinical knowledge and research. Clin. Med. (Lond) 20: 124-127.   DOI
18 Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. 2020. Clinical characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 382: 1708-1720.   DOI
19 Weiss P, Murdoch DR. 2020. Clinical course and mortality risk of severe COVID-19. Lancet 395: 1014-1015.   DOI
20 Lee JY, Bae S, Myoung J. 2019. Middle east respiratory syndrome Coronavirus-encoded accessory proteins Impair MDA5-and TBK1-Mediated Activation of NF-kappaB. J. Microbiol. Biotechnol. 29: 1316-1323.   DOI
21 Lee J, Bae S, Myoung J. 2019. Generation of full-length infectious cDNA clones of middle east respiratory syndrome Coronavirus. J. Microbiol. Biotechnol. 29: 999-1007.   DOI
22 Ashburn TT, Thor KB. 2004. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3: 673-683.   DOI
23 Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 382: 1787-1799.   DOI
24 Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. 2020. Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med. 382: 2327-2336.   DOI
25 Kim HS, Lee K, Kim SJ, Cho S, Shin HJ, Kim C, et al. 2018. Arrayed CRISPR screen with image-based assay reliably uncovers host genes required for coxsackievirus infection. Genome Res. 28: 859-868.   DOI
26 Wang S, Liu Y, Guo J, Wang P, Zhang L, Xiao G, et al. 2017. Screening of FDA-Approved drugs for Inhibitors of Japanese Encephalitis Virus infection. J. Virol. 91: e01055-17.
27 Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30: 269-271.   DOI
28 Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. 2006. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J. Virol. 80: 5059-5064.   DOI
29 Amery WK. 1983. Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Headache 23: 70-74.   DOI
30 Ishii M, Kobayashi S, Ohkura M, Yamamoto R, Shimizu S, Kiuchi Y. 2009. Inhibitory effect of lomerizine, a prophylactic drug for migraines, on serotonin-induced contraction of the basilar artery. J. Pharmacol. Sci. 111: 221-225.   DOI
31 Perin PM, Haid S, Brown RJ, Doerrbecker J, Schulze K, Zeilinger C, et al. 2016. Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. Hepatology 63: 49-62.   DOI
32 Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM, Stossel A, et al. 2015. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci. Transl. Med. 7: 290ra289.
33 Nathan L, Lai AL, Millet JK, Straus MR, Freed JH, Whittaker GR, et al. 2020. Calcium ions directly interact with the Ebola virus fusion peptide to promote structure-function changes that enhance infection. ACS Infect. Dis. 6: 250-260.   DOI
34 Guo J, Li W, Wu Y, Jing X, Huang J, Zhang J, et al. 2017. Meclizine prevents ovariectomy-induced bone loss and inhibits osteoclastogenesis partially by upregulating PXR. Front. Pharmacol. 8: 693.   DOI
35 Wibble T, Engstrom J, Verrecchia L, Pansell T. 2020. The effects of meclizine on motion sickness revisited. Br. J. Clin. Pharmacol. 86: 1510-1518.   DOI